IP Library › Granted Patent US 12,203,070
Granted Patent B2
US 12,203,070 · App. 16/881,919 · Granted Jan 21, 2025

Gene knockout of NRF2 for treatment of cancer

Inventors: Eric Kmiec (Middletown, DE); Pawel Bialk (Wilmington, DE)
Assignee: Christiana Care Gene Editing Institute, Inc.
C12N15/113A61K31/7105C12N9/22C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,203,070
App. No.
16/881,919
Granted
Jan 21, 2025
Kind
B2
Abstract

The disclosure provides a guide RNA (gRNA) comprising a DNA-binding domain and a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease protein-binding domain, wherein the DNA-binding domain is complementary to a target domain from an NRF2 gene. The disclosure also provides nucleic acid sequence encoding the gRNA. The disclosure further provides a method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease and a guide RNA that is complementary to a target domain from an NRF2 gene in the subject. Methods of treating cancer comprising administering a pharmaceutical composition comprising: a DNA sequence encoding a guide RNA that is complementary to a target domain from an NRF2 gene in the subject; and a nucleic acid sequence encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, are also provided.

Claims (15)

1. A method of reducing cancer cell proliferation comprising introducing into a cancer cell (a) one or more DNA sequences encoding one or more guide RNAs (gRNAs) that are complementary to one or more target sequences in the human NRF2 gene, wherein the human NRF2 gene comprises at least exons 2, 3, 4 and 5 and (b) a nucleic acid sequence encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, whereby the one or more gRNAs hybridize to the human NRF2 gene and the CRISPR-associated endonuclease cleaves the human NRF2 gene, and wherein human NRF2 gene expression or activity is reduced in the cancer cell relative to a cancer cell in which the one or more DNA sequences encoding the one or more gRNAs and the nucleic acid sequence encoding the CRISPR-associated endonuclease are not introduced thereby reducing proliferation of the cancer cell by at least 5% relative to a cancer cell that is not treated with the one or more DNA sequences of (a) and the nucleic acid sequence of (b); wherein the cancer cell is a non-small-cell lung cancer cell, a head and neck cancer cell, or an esophageal squamous cancer cell.

2. The method of claim 1 , wherein the one or more gRNAs are complementary to one or more target sequences in exon 2, exon 3, exon 4, and/or exon 5 of the human NRF2 gene.

3. The method of claim 1 , wherein the one or more gRNAs comprise a trans-activated small RNA (tracrRNA) and a CRISPR RNA (crRNA).

4. The method of claim 1 , wherein the one or more gRNAs are one or more single guide RNAs.

5. The method of claim 1 , wherein the CRISPR-associated endonuclease is a class 2 CRISPR-associated endonuclease.

6. The method of claim 5 , wherein the class 2 CRISPR-associated endonuclease is Cas9 or Cas12a.

7. The method of claim 1 , wherein expression of one or more allele(s) of the human NRF2 gene is reduced in the cancer cell.

8. A method of reducing cancer cell proliferation comprising introducing into a cancer cell (a) one or more guide RNAs (gRNAs) that are complementary to one or more target sequences in the human NRF2 gene, wherein the human NRF2 gene comprises at least exons 2, 3, 4, and 5 and (b) a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, whereby the one or more gRNAs hybridize to the human NRF2 gene and the CRISPR-associated endonuclease cleaves the human NRF2 gene, and wherein human NRF2 gene expression or activity is reduced in the cancer cell relative to a cancer cell in which the one or more gRNAs and the CRISPR-associated endonuclease are not introduced thereby reducing proliferation of the cancer cell by at least 5% relative to a cancer cell that is not treated with the one or more gRNAs of (a) and the CRISPR-associated endonuclease of (b); wherein the cancer cell is a non-small-cell lung cancer cell, a head and neck cancer cell, or an esophageal squamous cancer cell.

9. The method of claim 1 , further comprising introducing one or more chemotherapeutic agents into the cancer cell.

10. The method of claim 9 , wherein the one or more chemotherapeutic agents are selected from the group consisting of cisplatin, vinorelbine, carboplatin, and a combination thereof.

11. The method of claim 8 , further comprising introducing one or more chemotherapeutic agents into the cancer cell.

12. The method of claim 11 , wherein the one or more chemotherapeutic agents are selected from the group consisting of cisplatin, vinorelbine, carboplatin, and a combination thereof.

13. The method of claim 2 , wherein the one or more gRNAs are complementary to one or more target sequences in exon 4 of the human NRF2 gene.

14. The method of claim 8 , wherein the one or more gRNAs are complementary to one or more target sequences in exon 2, exon 3, exon 4, and/or exon 5 of the human NRF2 gene.

15. The method of claim 14 , wherein the one or more gRNAs are complementary to one or more target sequences in exon 4 of the human NRF2 gene.

Assignments (3)
CHANGE OF NAME Recorded Nov 2, 2022
From: CHRISTIANA CARE GENE EDITING INSTITUTE, LLC
To: CHRISTIANA CARE GENE EDITING INSTITUTE, INC.
Reel/Frame 061874/0983 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2022
From: CHRISTIANA CARE HEALTH SERVICES, INC.
To: CHRISTIANA CARE GENE EDITING INSTITUTE, LLC
Reel/Frame 061511/0231 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2020
From: KMIEC, ERIC; BIALK, PAWEL
To: CHRISTIANA CARE HEALTH SERVICES, INC.
Reel/Frame 053385/0565 →
Continuity (2)
Provisional Application 62852076 · May 23, 2019
Related Publication 20200370047A1 · Nov 26, 2020
References Cited (99)
CN 105316324 · 2016 [cited by applicant]
CN 106520772 · 2017 [cited by applicant]
KR 1020090100775 · 2009 [cited by applicant]
WO 2016161207 · 2016 [cited by applicant]
WO WO2016161207A1 · 2016 [cited by examiner]
WO 2017201497 · 2017 [cited by applicant]
WO 2017201527 · 2017 [cited by applicant]
WO 2018009525 · 2018 [cited by applicant]
WO WO2018009939A1 · 2018 [cited by examiner]
WO 2019016772 · 2019 [cited by applicant]
Sundaresan et al. (Cell Reports, 2017, 21, 3728-3739). [cited by examiner]
Murray et al. (Chem Res Toxicol, 2019, 32, 2538-2551). [cited by examiner]
Perez-Pinera et al. (Nature Methods, 10, 10, 2013, 973-978). [cited by examiner]
Lau et al. (Pharmacological Research, 58, 2008, 262-270). [cited by examiner]
Bialk et al. (Molecular Therapy: Oncolytics, 11, 2018, 75-89). [cited by examiner]
Ma et al. (Ann. N.Y. Acad. Sci. 1434 (2018) 164-172). [cited by examiner]
F.C. Passero et al., “Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma”, BJH British Journal of Haematology, Jun. 13, 2019, John Wiley & Sons, Ltd. [cited by applicant]
S. Menogen et al., “The Dual Roles of NRF2 in Cancer”, Trends in Molecular Medicine, Jul. 2016, vol. 22, No. 7, Elsevier Ltd. [cited by applicant]
P. Bialk et al., “Functional Gene Knockout of NRF2 Increases Chemosensitivity of Human Lung Cancer A549 Cells InVitro and in a Xenograft Mouse Model”, Molecular Therapy Oncolytics, Dec. 2018, vol. 11. [cited by applicant]
H. Cho et al., “Functional Polymorphisms in NRF2: Implications for Human Disease”, Free Radical Biology and Medicine, 2015, vol. 88, 362-372. [cited by applicant]
T. Shibata et al., “Cancer Related Mutations in NRF2 Impair Its Recognition by Keap1-Cul3 E3 Ligase and Promote Malignancy”, PNAS, Sep. 9, 2008, vol. 105, No. 36. [cited by applicant]
J. Shao et al., “Impact of NRF2 on Tumour Growth and Drug Sensitivity in Oncogenic K-ras-Transformed Cells In Vitro and In Vivo”, Free Radical Research, 2018, vol. 52, No. 6, 661-671. [cited by applicant]
C. Sun et al., “Oligomeric proanthocyanidins protects A549 cells against H2O2-induced oxidative stress via the Nrf2-ARE pathway”, International Journal of Molecular Medicine, 39:1548-1554, 2017. [cited by applicant]
M. Gong et al., “Stable knockout of NRF2 gene in human A549 lung cancer cells by CRISPR/Cas9 system and its functional research”, China Oncology, 2019 vol. 29 No. 11. [cited by applicant]
K. Banas et al., “Temporal analyses of CRISPR-directed gene editing on NRF2, a clinically relevant human gene involved in chemoresistance”, BioRxiv, Oct. 10, 2019, http://dx.doi.org/10.1101/799676. [cited by applicant]
J. Strich et al., “CRISPR-Cas Biology and Its Application to Infectious Diseases”, Journal of Clinical Microbiology, Apr. 2019, vol. 57, Issue 4, 1-14. [cited by applicant]
Eric B. Kmiec (2019) “CRISPR-Directed Gene Editing in a Community Cancer Center”, Oncology Issues, 34:1, 30-37. [cited by applicant]
S. Wert et al., “Transcriptional Elements from the Human SP-C Gene Direct Expression in the Primordial Respiratory Epithelium of Transgenic Mice”, Developmental Biology, 156, 426-443, 1993. [cited by applicant]
B. Davidson et al., “A model system for in vivo gene transfer into the central nervous system using an adenoviral vector”, Nature Genetics, vol. 3, Mar. 1993, 219-223. [cited by applicant]
A. Anchini et al., “The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy”, Cancer Immunology, Immunotherapy (2018) 67:10… [cited by applicant]
G. Le Gal La Salle et al., “An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain”, Science , Feb. 12, 1993, New Series, vol. 259, No. 5097 (Feb. 12, 1993), pp. 988-990. [cited by applicant]
M. Kaplitt et al., “Long-term gene expression and phenotypic correction using adena-associated virus vectors in the mammalian brain”, Nature Genetics vol. Oct. 8, 1994. [cited by applicant]
E. Batrakova et al., “Using exosomes, naturally-equipped nanocarriers, for drug delivery”, Journal of Controlled Release 219 (2015) 396-405. [cited by applicant]
A. Hayden et al., “The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer”, Urologic Oncology: Seminars and Original Investigations 32 (2014) 806-814. [cited by applicant]
Y. Zhou et al., “Adenovirus-delivered wwox inhibited lung cancer growth in vivo in a mouse model”, Cancer Gene Therapy (2016) 23, 1-6. [cited by applicant]
P. Pandey et al., “The see-saw of Keap1-Nrf2 pathway in cancer”, Critical Reviews in Oncology/Hematology 116 (2017) 89-98. [cited by applicant]
S. Menegon et al., “The Dual Roles of NRF2 in Cancer”, Trends in Molecular Medicine, Jul. 2016, vol. 22, No. 7, 578-93. [cited by applicant]
Y. Zhou et al., “Over-expression of PDGF-C using a lung specific promoter results in abnormal lung development”, Transgenic Res (2006) 15:543-555. [cited by applicant]
Q. Li et al., “Molecular Characterization of the Promoter Region of a Neuroendocrine Tumor Marker, IA-1”, Biochemical and Biophysical Research Communications 236, 776-781 (1997). [cited by applicant]
S. Murakami et al., “Roles of Nrf2 in cell proliferation and differentiation”, FreeRadicalBiologyandMedicine88(2015) 168-178. [cited by applicant]
S. Kim et al., “Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting”, Journal of Controlled Release 266 (2017) 8-16. [cited by applicant]
M.D. Hellmann, “Chemotherapy remains an essential element of personalized care for persons with lung cancers”, Annals of Oncology 27: 1829-1835, 2016. [cited by applicant]
A. Bianco et al., “Targeting immune checkpoints in non small cell lung cancer”, Current Opinion in Pharmacology 2018, 40:46-50. [cited by applicant]
M. Rosenfeld et al., “In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium”, Cell, vol. 68, 143-155, Jan. 10, 1992. [cited by applicant]
K. Makarova et al., “Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants”, Nature Reviews Microbiology, vol. 18, Feb. 2020. [cited by applicant]
A. Singh et al., “Gain of Nrf2 Function in Non-Small-Cell Lung Cancer Cells Confers Radioresistance”, Antioxidants & Redox Signaling, vol. 13, No. 11, 2010, 1627-1637. [cited by applicant]
T. Scholzen et al., “The Ki-67 Protein: From the Known and the Unknown”, Journal of Cellular Physiology 182:311-322 (2000). [cited by applicant]
V. Velma et al., “Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells”, Biomarker Insights 2016:11, 113-121. [cited by applicant]
Y. Mitsuishi et al., “Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming”, Cancer Cell 22, 66-79, Jul. 10, 2012. [cited by applicant]
A. Geller et al., “Long-term increases in neurotransmitter release from neuronal cells expressing a constitutively active adenylate cyclase from a herpes simplex virus type 1 vector”, Proc. Natl. Acad. Sci., vol. 90, pp… [cited by applicant]
A. Geller et al., “Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of [cited by applicant]
Y. Fu et al., “Improving CRISPR-Cas nuclease specificity using truncated guide RNAs”, Nat Biotechnol. Mar. 2014 ; 32(3): 279-284. [cited by applicant]
L. Torrente et al., “Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses”, Oncogene (2017) 36, 6204-6212. [cited by applicant]
B. Quantin et al., “Adenovirus as an expression vector in muscle cells in vivo”, Proc. Nadl. Acad., vol. 89, pp. 2581-2584, Apr. 1992. [cited by applicant]
B. Jung et al., “Dysregulation of NRF2 in Cancer: from Molecular Mechanisms to Therapeutic Opportunities”, Biomol Ther 26(1), 57-68 (2018). [cited by applicant]
H. Funaki et al., “Localization and expression of AQP5 in cornea, serous salivary glands, and pulmonary epithelial cells”, Am J Physiol, 275, C1151-1157, 1998. [cited by applicant]
T. Fukutomi et al., “Kinetic, Thermodynamic, and Structural Characterizations of the Association between Nrf2-DLGex Degron and Keap1”, Molecular and Cellular Biology, Mar. 2014, vol. 34, No. 5, 832-846. [cited by applicant]
N. Sanjana et al., “Improved vectors and genome-wide libraries for CRISPR screening”, Nat Methods. Aug. 2014 ; 11(8): 783-784. [cited by applicant]
H. Kitamura et al., “NRF2 addiction in cancer cells”, Cancer Science. 2018;109:900-911. [cited by applicant]
M. Kerins et al., “A catalogue of somatic NRF2 gain of-function mutations in cancer”, Scientific Reports, (2018) 8:12846. [cited by applicant]
A. Geller et al., “An HSV-1 Vector Expressing Tyrosine Hydroxylase Causes Production and Release of L-DOPA from Cultured Rat Striatal Cells”, J Neurochem. Feb. 1995 ; 64(2): 487-496. [cited by applicant]
F.P. Fabrizio et al., “Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs”, Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 2492063, 2… [cited by applicant]
Y. Chen et al., “Expression of ssDNA in Mammalian Cells”, BioTechniques 34:167-171 (Jan. 2003). [cited by applicant]
L. You et al.,, “ONYX-015 Works Synergistically with Chemotherapy in Lung Cancer Cell Lines and Primary Cultures Freshly Made from Lung Cancer Patients”, Cancer Research 60, 1009-1013, Feb. 15, 2000. [cited by applicant]
Y. Wang et al., “Beta1-Integrin Deletion From the Lens Activates Cellular Stress Responses Leading to Apoptosis and Fibrosis”, IOVS, Aug. 2017, vol. 58, No. 10, 3896-3922. [cited by applicant]
T. Fukazawa et al., “Development of a Cancer-Targeted Tissue-Specific Promoter System”, Cancer Research 64, 363-369, Jan. 1, 2004. [cited by applicant]
R. Frank et al., “Clinical and Pathological Characteristics of KEAP1-and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC)”, Clinical Cancer Research, 2018, 3087-3097. [cited by applicant]
Y. Yang et al., “Cellular and Humoral Immune Responses to Viral Antigens Create Barriers to Lung-Directed Gene Therapy with Recombinant Adenoviruses”, Journal of Virology, Apr. 1995, vol. 69, No. 4, 2004-2015. [cited by applicant]
M. Strayer et al., Pre- and Postnatal Lung Development, Maturation, and Plasticity Human surfactant protein B promoter in transgenic mice: temporal, spatial, and stimulus-responsive regulation, Am J Physiol Lung Cell Mo… [cited by applicant]
L.D. Stratford-Perricaudet et al., “Widespread long-term gene transfer to mouse skeletal muscles and heart”, J Clin Invest. 1992;90(2):626-630. [cited by applicant]
B. Nounamo et al., “Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model”, Molecular Therapy: Oncolytics vol. Sep. 6, 2017, 91-99. [cited by applicant]
A. Namani et al., “Modulation of NRF2 signaling pathway by nuclear receptors:Implications for cancer”, Biochimica et Biophysica Acta 1843 (2014) 1875-1885. [cited by applicant]
D. Li et al., “Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer”, Cancer Gene Therapy (2013) 20, 251-259. [cited by applicant]
E. Koonin et al., “Diversity, classification and evolution of CRISPR-Cas systems”, Curr Opin Microbiol. Jun. 2017 ; 37: 67-78. [cited by applicant]
P. Bialk et al., “Functional Gene Knockout of NRF2 Increases Chemosensitivity of Human Lung Cancer A549 Cells In Vitro and in a Xenograft Mouse Model”, Molecular Therapy: Oncolytics vol. 11 Dec. 2018, 75-89. [cited by applicant]
J. Rock et al., “Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling”, Disease Models & Mechanisms 3, 545-556 (2010), 545-556. [cited by applicant]
L. Marek et al., “Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells”, Mol Pharmacol 75:196-207, 2009. [cited by applicant]
M. Bruno et al., “Lung cell-specific Expression of the Murine Surfactant Protein A (SP-A) Gene Is Mediated by Interactions between the SP-A Promoter and Thyroid Transcription Factor-1”, The Journal of Biological Chemist… [cited by applicant]
J. Strich et al., “CRISPR-Cas Biology and Its Application to Infectious Diseases”, Journal of Clinical Microbiology, vol. 57, Issue 4, Apr. 2019. [cited by applicant]
G. Simpson et al., “Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances”, Oncolytic Virotherapy 2016:5 1-13. [cited by applicant]
T. Shibata et al., “Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy”, PNAS, Sep. 9, 2008, vol. 105, No. 36, 13568-13573. [cited by applicant]
T. Shibata et al., “NRF2 Mutation Confers Malignant Potential and Resistance to Chemoradiation Therapy in Advanced Esophageal Squamous Cancer”, Neoplasia, vol. 13, No. 9, Sep. 2011, 864-873. [cited by applicant]
L. Ostrowski et al., “Targeting Expression of a Transgene to the Airway Surface Epithelium Using a Ciliated Cell-Specific Promoter”, Molecular Therapy vol. 8, No. 4, Oct. 2003, 637-645. [cited by applicant]
J. Liu et al., “CRISPR-CasX is an RNA-dominated enzyme active for human genome editing”, Nature. Feb. 2019 ; 566(7743): 218-223. [cited by applicant]
H. Kang et al., “HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction”, Scientific Reports, 4:7201, 2014. [cited by applicant]
A. Cheung et al., “Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9”, Laboratory Investigation (2018) 98:968-976. [cited by applicant]
M. Wang et al., “UVA Irradiation Enhances Brusatol-Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2-Mediated Antioxidant Response”, Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 97… [cited by applicant]
B. Stripp et al., “cis-Acting Elements That Confer Lung Epithelial Cell Expression of the CC10 Gene”, The Journal of Biological Chemistry, vol. 267, No. 21, Issue of Jul. 25, pp. 14703-14712, 1992. [cited by applicant]
M. Dong et al., “Advanced Malignant Pleural or Peritoneal Effusion in Patients Treated with Recombinant Adenovirus p53 Injection plus Cisplatin”, The Journal of International Medical Research, 2008; 36(6) 2. [cited by applicant]
Y. Chow et al., “Development of an epithelium-specific expression cassette with human DNA regulatory elements for transgene expression in lung airways”, Proc. Natl. Acad. Sci., vol. 94, pp. 14695-14700, Dec. 1997. [cited by applicant]
E. Brinkman et al., “Easy quantitative assessment of genome editing by sequence trace decomposition”, Nucleic Acids Research, 2014 1-8. [cited by applicant]
Sep. 4, 2020 International Search Report for corresponding PCT Appln. No. PCT/US2020/034322. [cited by applicant]
Sep. 4, 2020 International Written Opinion for corresponding PCT Appln. No. PCT/US2020/034322. [cited by applicant]
International Preliminary Report on Patentability pertaining to co-pending International Application No. PCT/US2020/034322, dated Nov. 16, 2021—pp. 1-8. [cited by applicant]
Moya-Garcia, Christian R., et al., “In Vitro Models for Head and Neck Cancer: Current Status and Future Perspective”, Frontiers in Oncology, Aug. 3, 2022, vol. 12, pp. 1-26. [cited by applicant]
Lu, Bao-Cai, et al., “Elevated Expression of NRF2 Mediates Multidrug Resistance in CD133+ Head and Neck Squamous Cell Carcinoma Stem Cell”, Oncology Letters, Oct. 17, 2016, vol. 12, pp. 4333-4338. [cited by applicant]
Syu, Jhih-Pu, et al., “NRF2 is the key to Chemotherapy Resistance in MCF7 Breast Cancer Cells Under Hypoxia”, Oncotarget, Feb. 15, 2016, vol. 7, No. 12, pp. 14659-14672. [cited by applicant]
Yuwen, Tao, et al., “Nuclear Factor-Erythroid 2—Related Factor 2 as a Potential Target for Colorectal Cancer Chemoprevention”, Acta Univ Med Nanjing, Jul. 2018, vol. 38, No. 8, pp. 1004-1008. [cited by applicant]
Changliang, Su, et al., “The Role of NRF2 in Promoting Tumor Growth and Chemotherapeutic Resistance”, Herald of Medicine, Mar. 2015, vol. 34, No. 3, pp. 354-357. [cited by applicant]